Teva Pharmaceutical Industries Limited
NYSE•TEVA
CEO: Mr. Richard D. Francis
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1982-02-16
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Contact Information
Market Cap
$33.27B
P/E (TTM)
23.9
35.3
Dividend Yield
--
52W High
$37.35
52W Low
$12.47
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$4.71B+12.09%
4-Quarter Trend
EPS
$0.42-315.79%
4-Quarter Trend
FCF
$1.02B+29.26%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Operating Income Rebounds Strongly Operating income reached $2.16B in 2025, reversing 2024's $303M loss, driven by favorable product mix.
Innovative Products Drive Revenue Total revenues grew 4% to $17.26B, primarily due to higher sales from AUSTEDO, AJOVY, and UZEDY growth engines.
US Segment Profit Surges United States segment profit increased 46% to $3.36B on $9.19B revenues, reflecting strong execution in core market.
Debt Reduction Achieved Consolidated debt decreased to $16.81B by year-end 2025, supported by cash flow generation and debt repayments.
Risk Factors
Generic Price Erosion Continues Generic sales, 55% of total revenue, face ongoing price erosion, requiring constant complex, high-value product launches.
Regulatory and Litigation Exposure Significant ongoing legal exposure remains, including opioid settlements and complex pricing/regulatory scrutiny globally.
Macroeconomic Headwinds Persist Fluctuating foreign exchange rates and inflation impact operating costs and supply chain stability across global operations.
Innovative Portfolio Success Reliance Future success heavily depends on maximizing growth of AUSTEDO, AJOVY, and UZEDY against emerging competition.
Outlook
Accelerate Growth Strategy Phase Executing "Accelerate Growth" phase focusing capital allocation on high-value innovative portfolio and operational efficiency savings.
Pipeline Advancement Focus Progressing late-stage innovative pipeline assets, including NDA filing for olanzapine LAI in December 2025.
API Business Divestiture Maintained Maintaining strategic intention to divest API business; initiated renewed sales process after prior exclusive discussions terminated.
AI Integration Initiatives Integrating AI technologies across operations to optimize processes, strengthen risk management, and support product research efforts.
Peer Comparison
Revenue (TTM)
$17.26B
$13.95B
$11.04B
Gross Margin (Latest Quarter)
97.8%
92.3%
78.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TEVA | $33.27B | 23.9 | 20.1% | 42.7% |
| BIIB | $26.64B | 20.6 | 7.3% | 23.6% |
| NTRA | $26.62B | -123.4 | -15.3% | 8.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.6%
Steady Growth
4Q Net Income CAGR
30.9%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:May 6, 2026
EPS:$0.59
|Revenue:$3.87B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data